Novo Nordisk and Hims & Hers reach partnership agreement on obesity medication

2026-03-07 15:40:34

Abstract generation in progress

Investing.com - According to Bloomberg News, Novo Nordisk and Hims & Hers Health plan to announce a new partnership as early as Monday to jointly sell obesity medications, ending their legal dispute.

The agreement marks a shift in the relationship between the Danish pharmaceutical giant and the telemedicine company. Novo Nordisk produces Wegovy and Ozempic, two blockbuster drugs used for weight loss and diabetes treatment.

Hims & Hers previously offered a compounded version of semaglutide, the active ingredient in Novo Nordisk’s drugs, through its telemedicine platform. This move drew the attention of Novo Nordisk, which sought to protect its branded products.

The collaboration will enable both companies to work together in the distribution of obesity medications rather than competing through legal means. Bloomberg did not disclose details of the business arrangement.

Novo Nordisk’s stock ticker on the New York Stock Exchange is NYSE:NVO, and Hims & Hers Health’s ticker is NYSE:HIMS.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.